Table 2.

Sensitivity analysis of the incidence of endocrine, cardiovascular, gastrointestinal, and psychiatric disorders in the 77 patients diagnosed with a sporadic insulinoma in Finland during 1980–2010, and in 308 matched controls, after the diagnosis of insulinoma, excluding the first year after diagnosis.

Disease	Patientsa			Controls			Patients vs controls		P-value
	n/n at riskb	Incidence rate/10 000/year	95% CI	n/n at riskb	Incidence rate/10 000/year	95% CI	Rate ratio	95% CI
Endocrine disordersc	7/52	107.19	51.10–224.85	27/219	91.76	62.93–133.80	1.17	0.51–2.68	0.714
Thyroid disorders	3/69	34.88	11.25–108.13	9/296	22.87	11.90–43.96	1.53	0.41–5.63	0.524
Parathyroid disorders	1/72	11.07	1.56–78.59	0/308	0.00		NA
Other endocrine disorders	1/61	12.56	1.77–89.13	1/262	2.74	0.39–19.43	4.59	0.29–73.34	0.236
Cardiovascular diseases	12/44	220.51	125.23–388.29	44/147	227.49	169.29–305.69	0.97	0.51–1.84	0.924
Atrial fibrillation and flutter	10/70	121.66	65.46–226.11	20/274	58.34	37.64–90.42	2.09	0.98–4.46	0.052
Gastrointestinal diseases	13/46	262.06	152.16–451.31	38/175	169.19	123.11–232.51	1.55	0.83–2.91	0.170
Other bowel diseases	11/68	138.54	76.72–250.16	26/279	70.39	47.93–103.38	1.97	0.97–3.98	0.055
Intestinal obstruction	4/72	46.07	17.29–120.00	1/307	2.43	0.34–17.25	18.96	2.12–169.64	<0.001
Diseases of the pancreas	1/66	11.99	1.69–85.09	3/263	9.04	2.91–28.02	1.33	0.14–12.75	0.806

Bold value indicates a statistically significant difference between the patients and the controls (P  < 0.05, Mantel–Haenszel method). When the Bonferroni correction for multiple comparisons is applied, a P value <0.005 (<0.05/10) is considered statistically significant.

^aTwo patients with MEN1 syndrome were excluded from the analyses, together with their corresponding controls; ^bPatients with a disease diagnosed before or within 1 year after the diagnosis of insulinoma were excluded from the incidence calculations of that disease category, together with their corresponding controls. Controls with a given disease diagnosed before or within 1 year after the diagnosis of insulinoma of the corresponding patient, as well as patients and controls with an insufficient follow-up time (less than a year after the diagnosis of insulinoma) were excluded individually; ^cExcluding hyperinsulinism and hypoglycaemia.

NA, not applicable.